Citation

Bakács T, Mehrishi JN. Vaccine 2004; 23(1): 3-13.

Copyright

(Copyright © 2004, Elsevier Publishing)

DOI

10.1016/j.vaccine.2004.08.005

PMID

unavailable

Abstract

Hepatitis virus infection persistent worldwide (∼600 m people) results in chronic hepatitis progressing to hepatocellular carcinoma (HCC) in many (∼1 m deaths/year). The review examines the usefulness of treating chronic viral hepatitis, including decompensated patients, by intentional coinfection with an attenuated infectious bursal disease virus (IBDV; apathogenic in man, stable at pH 2, orally administered). Learning lessons from the IBDV studies, the case is made to treat human immunodeficiency virus (HIV) infected patients (worldwide prevalence ∼50 m people) by coinfecting with apathogenic hepatitis G virus (GBV-C). These ideas are reinforced by (i) eight out of ten studies reporting a beneficial effect of GBV-C viremia on HIV-related mortality or response to therapy and (ii) the recent reports of improved or delayed survival of HIV patients, naturally coinfected with an apathogenic virus. © 2004 Elsevier Ltd. All rights reserved.

Language: en

Keywords

human; naloxone; survival; safety; depression; psychosis; mortality; suicide attempt; clinical trial; HIV; lamivudine; review; mental disease; autoimmune disease; patient care; Human immunodeficiency virus infection; priority journal; epidemiological data; anxiety disorder; neurotoxicity; nonhuman; health care cost; medical research; interferon; acquired immune deficiency syndrome; alpha interferon; hepatitis C; chlorpromazine; Hepatitis C virus; ribavirin; thyroiditis; hematologic disease; Human immunodeficiency virus; hypothyroidism; hepatitis B; antivirus agent; experimental model; cancer vaccine; alpha2b interferon; peginterferon alpha2a; thyroid disease; add on therapy; adefovir dipivoxil; beta interferon; cell interaction; central nervous system disease; Chronic decompensated viral hepatitis; Coinfection; duck; experimental animal; gamma interferon; GB virus C; Graves disease; heparin; Hepatitis A virus; hepatitis B vaccine; Hepatitis B virus; hepatitis C vaccine; Hepatitis G virus; Hepatocellular carcinoma; infectious bursal disease virus; Infectious bursal disease virus; mepacrine; molecular dynamics; molecular interaction; phenothiazine derivative; prion disease; recombinant interferon; superinfection; thymosin; thymosin alpha1; virus genome; virus hepatitis; virus virulence